Can a single dose of psilocybin help people with constant suicidal thoughts?
Yes. In this small open-label trial, one 25-mg dose of psilocybin given alongside talk therapy led to large and lasting drops in suicidal thinking. By week 12, 70% of the 20 participants had little or no suicidal ideation, and no serious side effects occurred.
Chronic suicidal ideation means having suicidal thoughts that stick around for a long time. For some people, these thoughts persist even after they try several different treatments. The people in this study had major depression and had already failed at least two antidepressant treatments. They were exactly the kind of patients who usually run out of options.
Psilocybin is the active compound in what are often called “magic mushrooms.” Researchers used a lab-made, purified form rather than mushrooms picked from the ground. Each person took it once, in a supervised setting, with structured support before, during, and after the dose. That support included preparation sessions, a guided dosing day, and follow-up sessions to help make sense of the experience.
What the data show
The results were both fast and strong. Researchers measured suicidal thinking using the Modified Scale for Suicidal Ideation, or MSSI. By the week-3 primary checkpoint, scores fell sharply compared to the start, with a mean drop of about 14 points and a very large effect size of 1.73. In plain terms, an effect size that big means the change was hard to miss.
The improvement did not take weeks to appear. By the first week, suicidal thinking had already dropped significantly, with an even larger effect size of 2.11. The benefit also held up over time. At week 12, scores were still down by about 13 points, and 70% of participants, or 14 of the 20, had reached a near-zero level of suicidal ideation.
Depression improved right alongside the suicidal thoughts. Using the Montgomery-Asberg Depression Rating Scale, researchers saw significant drops at every check after the dose, with effect sizes ranging from 1.63 to 1.97. Importantly, no serious adverse events happened during the study.
Dr. Kumar’s Take
This study excites me because it tackles a problem most trials avoid. For years, people with active suicidal thoughts were shut out of psychedelic research because they were seen as too risky to include. That left the patients who may need rapid help the most without any answers. This trial flipped that thinking and made suicidal ideation the main target, not a footnote.
I want to be careful here, though. This was an open-label trial, which means everyone knew they were getting psilocybin. There was no placebo group and no blinding, so we cannot rule out the power of expectation. With only 20 people, the sample is small. These results are promising and worth real attention, but they are a starting point, not proof. The next step is a larger, randomized, controlled trial.
How the study was done
The trial ran from March 2022 to May 2025 as a single-arm study, meaning every participant received the same treatment. All 20 adults had chronic suicidal ideation, major depression diagnosed by standard criteria, and a history of at least two failed antidepressant trials. Each received one 25-mg dose of psilocybin wrapped inside a set therapy protocol.
The main question was how much suicidal thinking changed from the start to week 3. Researchers also tracked changes at weeks 1 and 12, along with depression scores at the same points. They used careful statistical methods to compare the time points and adjust for multiple comparisons, which lowers the chance of a false positive.
Practical Takeaways
- Do not try to treat suicidal thoughts with mushrooms on your own, since this study used a purified, measured dose given in a controlled medical setting with trained support.
- If you or someone you know has ongoing suicidal thoughts, reach out to a doctor or a crisis line now, because effective help is available today and should not wait for new treatments.
- Ask your psychiatrist about clinical trials if standard antidepressants have not worked, as research like this is how access to newer options slowly expands.
- Remember that the therapy wrapped around the dose, including preparation and follow-up sessions, appears to be a key part of how this approach works, not an optional extra.
Related Studies and Research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Single-dose psilocybin shows rapid, sustained antidepressant effects
- Mindfulness-based cognitive therapy for major depression: dose-response and BDNF
- SAMe augmentation in major depressive disorder: clinical trial
FAQs
How is psilocybin different from antidepressants for suicidal thoughts?
Standard antidepressants usually take weeks to work and must be taken every day. In this trial, a single dose of psilocybin eased suicidal thinking within the first week and the benefit lasted through 12 weeks. Other rapid options like ketamine can act fast too, but their antisuicidal effect often fades within a day. The lasting nature of the response here is what makes it stand out, though it still needs confirmation in larger trials.
Is psilocybin safe for people with depression and suicidal ideation?
In this small study, no serious adverse events occurred, which is reassuring given the high-risk group. That said, safety was tested in only 20 carefully screened people inside a tightly controlled clinical setting with medical and psychological support on hand. This does not mean psilocybin is safe to use casually or alone. People with certain conditions, such as a history of psychosis, are usually excluded from these trials for safety reasons.
Why does the study include therapy along with the psilocybin?
The psilocybin was never given by itself. Participants went through preparation sessions to get ready, a supervised dosing day, and integration sessions afterward to process the experience. Researchers believe this structured support helps people make lasting sense of what they go through during the dose. It is best to think of the drug and the therapy as one combined treatment rather than two separate things.
Bottom Line
A single 25-mg dose of psilocybin, paired with structured therapy, produced rapid and lasting drops in suicidal thinking and depression in a group of people who had run out of standard options. By week 12, most participants had little or no suicidal ideation, and no serious side effects were reported. Because this was a small, open-label trial without a placebo group, the findings are early rather than final. Still, they open a door for the very patients who have long been left out of this research, and they make a strong case for larger controlled studies.
